Jo Close
Chief Operating Officer
BiomeBank is building the future of microbial medicine, grounded in proven science and engineered for what the world needs next. The company has already delivered the first approved donor-derived microbiome drug for recurrent Clostridioides difficile infection, demonstrating the real-world impact of microbiome therapies. Now, with world-first technology to co-culture complex bacterial communities and the largest culture collection globally, BiomeBank is developing the next generation of innovative therapies and probiotics that push the boundaries of what’s possible. Our mission is simple but bold: to restore gut microbial ecology and transform human health.
